CellFE news

CellFE Biotech, a venture-backed startup focused on microfluidics-based platforms for cell and gene engineering, has announced the appointment of Kevin Gutshall as Chief Business Officer.

Gutshall’s background in biotech-focused business development promises to bring a wealth of industry expertise to the CellFE executive team. Gutshall most recently served as the VP of Strategy and Corporate Development on the senior leadership team at MaxCyte, where he led the

CEO and Co-Founder Alla Zamarayeva PhD presented recently at the Startup Showcase at the ASGCT 25th Annual Conference. The presentation covered how CellFE is leveraging microfluidics to address challenges in cell and gene therapy manufacturing and the business’s long-term vision for growth.

The American Society of Cell and Gene Therapy (ASGCT) is a global society of opinion leaders and innovators in the cell and gene therapy space. The annual meeting is a key event where members

CellFE Biotech, a gene therapy company focused on developing a microfluidics-based platform for cell engineering, will be attending the Bio Digital conference next week from June 14-18, 2021. While the conference will feature live and on-demand sessions, as well as presentations in the Innovation Stage, industry participants are able to use the events One-on-One Partnering feature for business development networking. The One-on-One digital format will allow participants to meet with industry